212 results about "Tumor Stem Cells" patented technology

A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell. We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumor cells in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells. We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.

A neoplastic stem cell population enriched for expression of the OCT4 transcription factor as well as methods for their identification, isolation and enrichment are described. The OCT4-enriched neoplastic stem cell population is further utilized for the induction and analysis of cancer in an animal. In addition, methods of preventing, abrogating, or inhibiting cancer, tumor growth, and metastasis via OCT4 inhibition are further provided.

The invention discloses application of active ingredients of juncus effuses in the preparation of medicaments for resisting tumors or inhibiting angiogenesis, health-care food or cosmetics. In the invention, the active ingredients of juncus effuses has the activity of inhibiting the tumors and tumor angiogenesis, and the prepared medicaments for inhibiting the tumors and the tumor angiogenesis can be used for treating or preventing malignancy and diseases relevant to the tumor angiogenesis and also can be used for treatment in tumor chemotherapy and / or auxiliary chemotherapy. In the application, the medicinal curative effect and effect mechanism of the active ingredients of juncus effuses are studied and clarified by taking tumor stem cells, tumor cells and tumor neoangiogenesis as targetspots for treating diseases so as to establish a foundation for the research and development of the active ingredients of juncus effuses and the innovative anti-tumor traditional Chinese medicines ofthe active ingredients and provide scientific basis and important information for the Chinese medicinal treatment of the malignancy.

The invention provides a circulating tumor stem cell detection kit based on magnetic beads and a microfluidic chip. The circulating tumor stem cell detection kit is characterized by comprising a microfluidic chip, at least one immunomagnetic bead, and at least one fluorescent antibody against a tumor stem cell biomarker, wherein the immunomagnetic bead can be specifically bonded with the circulating tumor stem cell and marked with the tumor stem cell biomarker; the microfluidic chip comprises a glass chip base; a microfluidic channel is arranged on the glass chip base; a soft magnetic micro-array is arranged inside the microfluidic channel. By adopting the circulating tumor stem cell detection kit, a plurality of different categories of rare circulating tumor stem cells can be captured and detected by sampling once, and the circulating tumor stem cell detection kit has high sensitivity and specificity, is convenient and fast to operate, can easily collect captured cells, and does not need complicated surface modification processes of a first antibody and a second antibody of the microfluidic channel inside the chip.

This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided.

A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise to both more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation and the ability to give rise to new tumors. Thus, solid tumor heterogeneity reflects the presence of tumor cell progeny arising from a solid tumor stem cell.We have developed a xenograft model in which we have been able to establish tumors from primary tumors via injection of tumors in the mammary gland of severely immunodeficient mice. These xenograft assay have allowed us to do biological and molecular assays to characterize clonogenic solid tumor stem cells.We have also developed evidence that strongly implicates the Notch pathway, especially Notch 4, as playing a central pathway in carcinogenesis.

The invention relates to the technical field of biomedical detection. By using an IncRNA chip to screen the IncRNA related to a tumor stem cell, the result shows that IncRNA-NEAT1 is highly expressed in the liver cancer stem cell and the liver cancer stem cell function can be adjusted. The invention discloses an application of the IncRNA-NEAT1 in preparation of a liver cancer diagnostic marker and an application of the IncRNA-NEAT1 in preparation of a detection reagent or a kit for diagnosing the liver cell. Moreover, the invention discloses a method for detecting the IncRNA-NEAT1 in a human serum and a kit for detecting the IncRNA-NEAT1 in the serum. Through the detection of the human serum of a liver cancer patient, the IncRNA-NEAT1 can be detected in the serum and the IncRNA-NEAT1 content in the serum of an HCC patient is obviously higher than a normal person. The kit provides a novel clinical solution for the liver cancer serological diagnosis.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The present invention comprises a method of detecting circular tumor cells and methods of detecting, evaluating, or staging cancer in a patient, as well as a method of monitoring treatment of cancer in a patient using the claimed method. The method comprises contacting a sample with a CD45 binding agent; selecting the cells based on positive or negative CD45 staining; contacting the selected cells with a labeled nucleic acid probe, and detecting hybridized cells by fluorescence in situ hybridization; and analyzing a signal produced by the labels on the hybridized cells to detect the CTCs. In other embodiments, the method provides for directed to a method of determining the level of CTCs in a sample having blood cells from a patient by contacting a sample having blood cells from a patient, wherein the sample has not been pre-sorted into CD45-positive and CD45-negative cells.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The invention provides a human tumor stem cell line T3A-A3, which is obtained by separation of liver cancer tissue excised in an operation of a primary hepatic carcinoma patient. The separated cells can be in long-term passage culture in vitro, can grow rapidly and retain stem cell property after more than 100 times of passage. The cell can express markers of multiple stem cells, has self-updatingcapability of stem cells and directional differentiation potentials for different tumor cells, and also has tumor property, tumorigenicity ability and metastatic ability. The invention is a powerfultool for preparing stem cell drugs for targeting tumor, due to the facts that the cells can be in long-term passage culture in vitro and retain unchanged stem cell property, and the tumorigenicity ability and metastatic ability thereof are strong in immunodeficient mice.

The present disclosure is directed to a composition for the sustained-release delivery of an active agent to a target cell of an individual. The compositions disclosed herein comprise of at least one porous particle; at least one polymer; and at least one active agent. In an embodiment, the porous particle comprises a plurality of microscale reservoirs. In an exemplary embodiment, the at least one active agent is covalently linked to the at least one polymer to form a polymer-active agent conjugate, and the polymer-active agent conjugate is contained in the plurality of microscale reservoirs of the porous particle. The present disclosure is also directed to a method of treating a tumor, comprising the step of administering to an individual the composition described supra. Additionally, disclosed herein is a method of eliminating tumor stem cells. Furthermore, there is provided a method of circumventing multi-drug resistance in a tumor cell.

The invention provides a tumor drug-loaded microparticle preparation and a preparation method thereof. The drug-loaded microparticle preparation includes tumor stem cell apoptosis released cell vesicles and a chemotherapeutic drug wrapped in the cell vesicles as an effective component; and is prepared by mixed culture of a three-dimensional soft fibrin glue and tumor cells in a medium. The tumor drug-loaded microparticle provided by the invention is more beneficial to high enrichment in tumor tissue and deep penetration of tumors and can achieve effective uptake by common tumor cells and tumorstem cells more easily, can improve the killing power of the chemotherapeutic drug to common tumor cells and tumor stem cells, can solve the problem that common tumor cell derived drug-loaded microparticles cannot permeate to the depth parts of tumors to kill a lot of tumor stem cells, and at the same time can reduce the toxic and side effect of the chemotherapeutic drug on the body.

The invention discloses applications of miR-455-3p in the diagnosis, treatment, and prognosis of esophageal squamous cancer. The inventor finds that the obviously low survival rate of ESCC patients is related with the high expression of miR-455-3p in ESCC patients. The in-vitro and in-vivo experiment results show that miR-455-3p is capable of promoting the malignant progression of ESCC, by inhibiting the expression of miR-455-3p, the ESCC stem cell characteristics can be inhibited, and the sensitivity of ESCC stem cells to chemotherapy drugs is enhanced; so an expression inhibitor of miR-455-3p can inhibit the tumor stem cells, and is capable of inhibiting the tumor stem cell characteristics and enhancing the sensitivity of the cancer stem cells to chemotherapy drugs. The invention finds the expression of miR-455-3p in cancer patients for the first time, and the expression can be used as auxiliary diagnosis and / or prognosis of ESCC. The invention provides a novel diagnosis method, a novel treatment method, and a pharmaceutical drug screening platform for tumor diseases.

The invention relates to dendritic cell (DC) tumor vaccine in which a multi-medicine resistance tumor stem cell antigen composition is loaded. The antigen composition loaded in the DC tumor vaccine derives from tumor tissues, and is mainly used for tumor stem cells; and specifically, the tumor tissues are subjected to tumor stem cell primary separation and culture so as to obtain the tumor stem cells, the tumor stem cells are screened by a flow cytometry so as to obtain tumor stem cells with multi-medicine resistance, and finally full cell antigens are prepared.

The invention belongs to the field of pharmacy, and particularly relates to whole process targeting polypeptide molecule targeting a brain capillary vessel endothelial cell, a tumor neovascular endothelial cell, a tumor mimic blood vessel, a tumor cell and a tumor stem cell, and a stable optimized polypeptide molecule thereof, and an application of modified compound and a drug delivery system in the diagnosis and treatment of tumors. The invention relates to the application of the whole process targeting polypeptide WVAP and a WVAP modified drug and a polymer carrier material, and the application thereof in the construction of tumor imaging and a targeted therapy delivery system, the results show that WVAP can cross a blood-brain barrier, can target tumor neovascularization and cross blood-tumor barrier, and target tumor mimicry blood vessels, the tumor cells and the cancer stem cells; the nano drug delivery system constructed by the WVAP modified polymer carrier material can effectively deliver the encapsulated drug into the brain, targets the tumor tissue, and significantly improves the antitumor efficacy.

The present invention relates to a new medical use of fenretinide or bioactive derivatives thereof, particularly to the use of fenretinide or bioactive derivatives thereof in the preparation of a medicament for eliminating or killing tumor stem cells in a subject or for treating and / or preventing a tumor disease originating from tumor stem cells in a subject. The invention further relates to a new use of fenretinide or bioactive derivatives thereof in combination with other anti-tumor agents, a pharmaceutical composition comprising said fenretinide or bioactive derivatives thereof and at least one additional anti-tumor agent, a method of screening said other anti-tumor agent, a method of eliminating or killing tumor stem cells or particularly hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof, as well as a method of eliminating or killing tumor stem cells and tumor cells derived from tumor stem cells, particularly hematologic tumor stem cells and hematologic tumor cells derived from hematologic tumor stem cells in a subject by administrating said fenretinide or bioactive derivatives thereof in combination with other anti-tumor agent(s).

The invention provides a dendritic cell carried by a tumor stem cell antigen and subjected to tolerance screening and a preparation method thereof, application of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening in preparing anti-tumor medicament, a kit for preparing the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening, and a vaccine comprising the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening. The dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening and the medicament prepared by an immune composition of the dendritic cell carried by the tumor stem cell antigen and subjected to the tolerance screening can kill tumor stem cells causing tumor relapse in vivo and in vitro so as to provide possibility for overcoming the tumor tolerance and radically treating the relapse and transfer of tumor.

The invention provides an enriching and screening method for tumor stem cell. The combination of ball culture and immunomagnetic beads separation method is used for enriching and screening the tumor stem cells, the details are as follows: continuously culturing the tumor cells in a no-serum ball culture medium, using the QPCR method to simultaneously examine the relative levels of tumor stem cell markers, when the expression levels of specific marker is relatively the highest, supplement with immunomagnetic and positive, single or double screening tumor stem cells. The combination of the two screening methods can significantly improve such practical problems as low separation rates, low purity levels and the inconveniences of after application for tumor stem cells.

The invention discloses a magnetic bead immunodetection kit for human colorectal cancer tumor stem cell markers CD44 and CD133, and belongs to the field of immunoglobulin. The kit comprises a Solution I, protease K, a fluorescent CD44 antibody and a magnetic bead CD133 antibody. Technology combining magnetic beads and fluorescence radiation is adopted in the kit for detecting CD44 and CD133 on cytomembranes, thereby saving tedious operation of a flow cytometry. A small quantity of a pathological sample of a patient is added in a kit with the magnetic bead antibody and the fluorescent antibody well prepared and is detected through a fluorescence microscope to get a result. The kit is simple to use, short in detection time and low in cost and has bright application prospects.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The invention provides a method for establishing a human nasopharyngeal carcinoma tumor stem cell line. The method comprises the following steps: (1) obtaining human nasopharyngeal carcinoma cells in the single cell state; (2) adding the human nasopharyngeal carcinoma cells in the single cell state, obtained in the step (1), to a serum-free stem cell culture medium containing epidermal growth factors and basic fibroblast growth factors to obtain single cell suspension; (3) adjusting the concentration of the single cell suspension in the step (2) to 900-1100 single cells / ml; (4) inoculating 1ml of the single cell suspension obtained in the step (3) into single pores on a cell culture six-pore plate and then adding the equivoluminal stem cell culture medium for culture for 72-96 hours; and (5) collecting the cells obtained in the step (4), carrying out trypsinization till the single cell and carrying out subculture. The method provided by the invention is simple and convenient to operate; and the obtained nasopharyngeal carcinoma stem cell line has obvious stem cell characteristics.

The invention discloses a separating method of tumor stem cells. The separating method comprises the following steps: digesting tumor cells into single cells, then, adding the single cells into a digestive enzyme liquid to hatch for several hours; then, adding the hatched cells into a cell culture fluid containing blood serum to perform adherence growth; after the cells are adhered, transferring the adhered cells into a tumor stem cell TSC culture medium to culture; and after the cells grow all over, repeating the operation for many times, performing microsphere culture on the obtained cells to finally obtain the microspheres which are the tumor stem cells. According to the separating method of the tumor stem cells disclosed by the invention, various digestive enzymes or other physical stress conditions are combined to stimulate various tumor cells, so that TSC in different types can be stably obtained. The MuseTSC separated by the separating method disclosed by the invention has extremely strong stem characteristic and good homogeneity, and is stable, and therefore, the method can be used for enabling the obtaining of the TSC in different types to be standard, relatively simple and economical, and suitable for constructing a TSC base on a large scale to meet the working needs of the conventional tumor biomedicine basic research, the clinical research, the medicine development, and the like.

The invention relates to a tumor stem cell marker CD133-targeting polypeptide and an application thereof. A general formula of the polypeptide is CX1X2X3X4X5X6X7X8LX9. The invention further relates to a DNA fragment encoding the polypeptide, an expression vector and host cell expressing the polypeptide, and a bivalent body, a multivalent body or a pharmaceutical composition formed by the polypeptide. The polypeptide is used for detecting and targeting the tumor stem cell, and is good in specificity and sensitivity, simple in preparation method, low in cost and high in practicability. The polypeptide is applied to near-infrared fluorescence imaging to carry out high-sensitivity and high-resolution monitoring and targeted therapy on the CD133 tumor stem cell in a skin transplatation tumor. Simple, fast, economical and accurate detection means can be provided for real-time monitoring of peripheral blood CD133 expression of a patient and the correlation of the CD133 tumor stem cell in tumor recurrence, metastasis, drug tolerance and prognosis, so that the therapeutic scheme is convenient to timely adjust and novel means can be provided for improving the prognosis of patients.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells.

The invention is based on observing that LIF is capable of activating the self-renewal of tumor stem cells in cancer, in particular gliomas, which indicates that the inhibition of LIF, and generally of IL-6 type cytokines, can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. The invention also relates to a method for the identification of compounds capable of blocking / inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of subjects suffering from said tumors.

The invention provides application of an extracting solution of natural multi-form arsenic. The extracting solution of natural multi-form arsenic is applicable to preparation of medicines for resisting tumor stem cell, resisting hepatitis B and resisting human immunodeficiency virus; the extracting solution of natural multi-form arsenic added with pharmaceutically acceptable auxiliaries can be prepared to be soft capsules, hard capsules, pills, tablets, granules, injections or powder injections, oral liquid, microcapsules, dropping pills, aerosol and suppository preparations, and can be taken by oral, injection or rectum. The extracting solution of natural multi-form arsenic can inhibit hepatitis B and resist human immunodeficiency virus and other viruses, and expands the applicable scope of natural arsenicals in development and utilization.

A method and composition for hyperthermally treating tumor cells in a patient under conditions that affect tumor stem cells and tumor cells. In one embodiment, the method provides a synergetic effect with chemotherapy.

The invention discloses a three-dimensional culture method for screening breast cancer stem cells. According to the three-dimensional culture method, hydrogel is adopted for conducting three-dimensional culture on the human breast cancer cells to directly obtain breast cancer stem cell microspheres which are in ESA+CD44+ / CD24- / low phenotypes and obviously have the characteristics of tumor stem cells. The method is a reliable breast cancer stem cell screening method. The method is simple to operate and has the advantages that the costs of reagent consumption, instrument usage, human resources and the like are greatly lowered compared with the prior art such as a flow cytometer screening method.